99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors

Nuclear Medicine Communications

Volumn 28, Issue 12, 2007, Pages 888-894

  Bleichner Perez, Sarah ^a   Le Jeune, Florence ^a   Dubois, Francois ^a   Steinling, Marc ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Brain tumors; Chemotherapy response; MIBI SPECT; Scintigraphy

Indexed keywords

FOTEMUSTINE; LOMUSTINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG UPTAKE; FEMALE; GLIOMA; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIMARY TUMOR; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR RECURRENCE; BRAIN TUMOR; METHODOLOGY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 37349110711     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3282f1646c     Document Type: Article

References (33)

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003; 36:323-331.
2. 201Tl SPECT imaging of brain tumors. J Nucl Med 2000; 41:5-10.
3. 11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006; 27:1432-1437.
4. 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 2005; 32:39-51.
5. Delmon-Moingeon LI, Piwnica-Worms D, Van Den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutylisonitrile) technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50:2198-2220.
6. Miller DD, Stratmann HG, Shaw L, Tamesis BR, Wittry MD, Younis LT, et al. Dipyridamole technetium-99m sestamibi myocardial tomography as an independent predictor of cardiac event-free survival after acute ischemic events. J Nucl Cardiol 1994; 1:72-82.
7. Palmedo H, Biersack HJ, Lastoria S, Maublant J, Prats E, Stegner HE, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998; 25:375-385.
8. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993; 53:977-984.
9. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Schubert EK, Tseng J, et al. [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow. Nucl Med Biol 2002; 29:719-727.
10. Zhou J, Higashi K, Ueda Y, Kodama Y, Guo D, Jisaki F, et al. Expression of multidrug resistance protein and messenger RNA correlate with (99m)Tc-MIBI imaging in patients with lung cancer. J Nucl Med 2001; 42:1476-1483.
11. Le Jeune FP, Dubois F, Blond S, Steinling M. Sestamibi technetium-99m brain single-photon emission computed tomography to identify recurrent glioma in adults: 201 studies. J Neurooncol 2006; 77:177-183.
12. 99mTc-MIBI brain spect (functional index ratios) and survival after treatment failure in malignant glioma patients. Anticancer Res 2002; 22:3081-3085.
13. 99mTc-sestamibi brain SPECT after chemoradiotherapy is prognostic of survival in patients with high-grade glioma. J Nucl Med 2004; 45:409-413.
14. Lamy-Lhullier C, Dubois F, Blond S, Lecouffe P, Steinling M. Importance of cerebral tomoscintigraphy using technetium-labeled sestamibi in the differential diagnosis of current tumor vs. radiation necrosis in subtentorial glial tumors in the adult. Neurochirurgie 1999; 45:110-117.
15. Prigent-Le Jeune F, Dubois F, Perez S, Blond S, Steinling M. Technetium-99m sestamibi brain SPECT in the follow-up of glioma for evaluation of response to chemotherapy: first results. Eur J Nucl Med Mol Imaging 2004; 31:714-719.
16. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JC. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
17. 201Tl. Neuroradiology 2001; 43:1023-1030.
18. Baillet G, Albuquerque L, Chen Q, Poisson M, Delattre JY. Evaluation of single-photon emission tomography imaging of supratentorial brain gliomas with technetium-99m sestamibi. Eur J Nucl Med 1994; 21:1061-1066.
19. m-sestamibi. Nucl Med Commun 1995; 16:258-264.
20. Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. Semin Nucl Med 2007; 37:34-47.
21. Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging 2005; 32:836-842.
22. 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 1998; 77:353-358.
23. Andrews DW, Das R, Kim S, Zhang J, Curtis M. Technetium-MIBI as a glioma imaging agent for the assessment of multi-drug resistance. Neurosurgery 1997; 40:1323-1332; discussion 1333-1334.
24. Nagamachi S, Jinnouchi S, Ohnishi T, Nakahara H, Flores L II, Tamura S, et al. The usefulness of Tc-99m MIBI for evaluating brain tumors: comparative study with Tl-201 and relation with P-glycoprotein. Clin Nucl Med 1999; 24:765-772.
25. 18F-fluorodeoxyglucose and single photon emission computed tomography with thallium-201 chloride. Neuroradiology 1998; 40:210-251.
26. 11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 2005; 103:498-507.
27. Tang BN, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 2005; 71:161-168.
28. De Witte O, Hildebrand J, Luxen A, Goldman S. Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 1994; 74:2836-2842.
29. Ogawa T, Uemura K, Shishido F, Yamaguchi T, Murakami M, Inugami A, et al. Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 1988; 12:290-297.
30. 18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000; 82:608-615.
31. Roesdi MF, Postma TJ, Hoekstra OS, Van Groeningen CJ, Wolbers JG, Heimans JJ. Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma. J Neurooncol 1998; 40:251-255.
32. O'Tuama LA, Treves S, Larar JN, Packard AB, Kwan AJ, Barnes PD, et al. Thallium-201 versus technetium-99m MIBI SPECT in evaluation of childhood brain tumors. J Nucl Med 1993; 34:1045-1051.
33. Soler C, Beauchesne P, Maatougui K, Schitt T, Barral FG, Michel D, et al. Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy. Eur J Nucl Med 1998; 25:1649-1657.